Port F K, Wolfe R A, Mauger E A, Berling D P, Jiang K
Michigan Kidney Registry, University of Michigan School of Medicine, Ann Arbor.
JAMA. 1993 Sep 15;270(11):1339-43.
To compare mortality risk among cadaveric renal transplant recipients vs transplant candidates on dialysis in the cyclosporine era.
Patient mortality risk was analyzed by treatment modality for a completed statewide patient population.
All Michigan residents younger than age 65 years who started endstage renal disease (ESRD) therapy between January 1, 1984, and December 31, 1989, were included. Patients were followed up from ESRD onset (n = 5020), to wait-listing for renal transplant (n = 1569), to receiving a cadaveric first transplant (n = 799), and to December 31, 1989.
Mortality rates.
Using a time-dependent variable based on the waiting time from date of wait-listing to transplantation and adjusting for age, sex, race, and primary cause of ESRD, the relative risk (RR) of dying was increased early after transplantation and then decreased to a beneficial long-term effect, given survival to 365 days after transplantation (RR, 0.36; P < .001). This lower long-term risk was most pronounced (RR, 0.25) among diabetic transplant recipients compared with diabetic wait-listed dialysis patients (P < .001) and not observed among patients with glomerulonephritis as cause of ESRD (P > .05). Overall, the estimated times from transplantation to equal mortality risk was 117 +/- 28 days and to equal cumulative mortality was 325 +/- 91 days.
The overall mortality risk following renal transplantation was initially increased, but there was a long-term survival benefit compared with similar patients on dialysis. These analyses allow improved description of comparative mortality risks for dialysis and transplant patients and allow advising patients regarding comparative survival outcomes.
比较环孢素时代尸体肾移植受者与接受透析的移植候选者的死亡风险。
通过治疗方式对全州范围内已完成的患者群体的患者死亡风险进行分析。
纳入了所有1984年1月1日至1989年12月31日开始接受终末期肾病(ESRD)治疗的年龄小于65岁的密歇根州居民。患者从ESRD发病(n = 5020)开始随访,直至列入肾移植等待名单(n = 1569)、接受首次尸体肾移植(n = 799),直至1989年12月31日。
死亡率。
采用基于从列入等待名单之日到移植的等待时间的时间依赖性变量,并对年龄、性别、种族和ESRD的主要病因进行校正,移植后早期死亡的相对风险(RR)增加,然后下降至具有长期有益效果,前提是移植后存活365天(RR,0.36;P <.001)。与列入等待名单的糖尿病透析患者相比,这种较低的长期风险在糖尿病移植受者中最为明显(RR,0.25)(P <.001),而在以肾小球肾炎为ESRD病因的患者中未观察到(P>.05)。总体而言,从移植到同等死亡风险的估计时间为117±28天,到同等累积死亡率的时间为325±91天。
肾移植后的总体死亡风险最初增加,但与接受透析的类似患者相比有长期生存益处。这些分析有助于更好地描述透析患者和移植患者的比较死亡风险,并为患者提供关于比较生存结果的建议。